Please assess the completion status of the following clinical trial:

Trial Title: Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Comply with all current Australian Schedule of Pharmaceutical Benefits S100 eligibility criteria.~* Chronic hepatitis C genotype 3 infection with a viral load of at least 2 million copies per mL.~* Able to give written informed consent.~* Understand and be able to adhere to the dosing and visit schedules.~* Compensated liver disease with the following minimum hematologic and biochemical criteria:~  * Hemoglobin ≥120 g/L (females), ≥130 g/L (males)~ * Platelets ≥100 x 10\^9/L~ * Neutrophil count ≥1.5 x 10\^9/L~ * Creatinine clearance \>50 mL/minute~ * Thyroid stimulating hormone (TSH) within normal limits~* Serum hepatitis B surface antigen (HBsAg) and human immunodeficiency virus (HIV) negative.~* Negative pregnancy test.~Exclusion Criteria:~* Suspected hypersensitivity to interferon, pegylated interferon alfa-2b, or ribavirin.~* Participation in any other investigational drug program within 30 days of the screening visit for this protocol.~* Any cause of liver disease based on patient history and biopsy other than chronic hepatitis C, including but not limited to: hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, autoimmune hepatitis, alcoholic liver disease, drug-related liver disease.~* Hepatocellular carcinoma.~* Decompensated cirrhosis (ascites, history of encephalopathy or bleeding varices, serum albumin \<35 g/L, prothrombin time (PT) prolonged by greater than 3 sec).~* Significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, myocardial infarction, severe hypertension, or significant arrhythmia) or participants with an ECG showing clinically significant abnormalities.~* Immunologically-mediated disease, (e.g. inflammatory bowel disease), idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis).~* Hemophilia or any hemoglobinopathy, including but not limited to thalassemia major.~* Severe psychiatric condition, including major depression, a history of major psychoses, current suicidal ideation, and/or suicidal attempts.~* Ongoing substance abuse, e.g. alcohol, I.V. drugs or inhalants that in the opinion of the investigator would jeopardize the patient's ability to comply with study requirements.~* Clinically significant ophthalmological disorders.~* Treatment or recent treatment with immunosuppressive agents (excluding short-term corticosteroid withdrawal) and immunosuppressed transplant recipients.~* Poorly controlled thyroid disease.~* Any other condition that in the opinion of the investigator would make the patient unsuitable for enrolment, or could interfere with the patient participating in and completing the clinical trial program.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 24 weeks of therapy (Type: ACTIVE_COMPARATOR): Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks
- 48 weeks of therapy (Type: EXPERIMENTAL): Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).